Cholecystokinin antagonists: pharmacological and therapeutic potential.
about
Involvement of endogenous CCK and CCK1 receptors in colonic motor functionThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsRole of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.Pharmacogenomics of neuropsychiatric disorders: analysis of genetic variability in 162 identified neuroreceptors using 1000 Genomes Project data.Screening a plant extract library for inhibitors of cholecystokinin receptor CCK1 pathways.Anthranilate-activating modules from fungal nonribosomal peptide assembly linesCholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in miceNeuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependenceEffects of itopride hydrochloride on plasma gut-regulatory peptide and stress-related hormone levels in healthy human subjects.Mechanisms of cholecystokinin-induced calcium mobilization in gastric antral interstitial cells of Cajal.Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potentialNetazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.Cell-type-specific CCK2 receptor signaling underlies the cholecystokinin-mediated selective excitation of hippocampal parvalbumin-positive fast-spiking basket cellsEffect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.Sensitivity of cholecystokinin receptors to membrane cholesterol content.Achlorhydria is associated with gastric microbial overgrowth and development of cancer: lessons learned from the gastrin knockout mouse.Structural basis of cholecystokinin receptor binding and regulation.Current and Emerging Medical Therapies for Gastroparesis.Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome.Synthesis of new 1,3,4-benzotriazepin-5-one derivatives and their biological evaluation as antitumor agents.Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.Cholecystokinin CCK2 receptors mediate the peptide's inhibitory actions on the contractile activity of human distal colon via the nitric oxide pathway.Regulation of membrane cholecystokinin-2 receptor by agonists enables classification of partial agonists as biased agonists.Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve.Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray.The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats.Linking non-peptide ligand binding mode to activity at the human cholecystokinin-2 receptor.Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
P2860
Q24671868-4CABD591-DD0F-4421-B03B-7C58A09FA8EBQ30486707-7C59455A-CBB3-46BD-A59B-48435200C9D3Q30487910-AA325C97-7F16-44C2-AE6F-321276E4EC22Q30863802-743899BC-7B9C-4F21-B569-9A0A89E0C194Q33575779-E9C1613B-5AC6-4AD5-932F-2853FAC8D724Q33787584-FAE431AC-35F8-457C-842E-7638265764A8Q34167464-F75FC694-EE80-48D3-9449-DA5AEA0649B7Q34275762-D6A97A1E-1F7E-49DD-AD5B-314A064C21ADQ34298025-F1624C31-76F8-457F-B143-6BBBACF67D97Q34529391-8B2F132B-B275-4E27-A4D4-AD0F0A9F7A70Q34550657-63D1D6C1-1FD7-4559-937A-36C3D4720BF7Q34712671-BA311FF7-4614-4289-A5EC-CEC7DF4837B6Q35009459-6C6401AA-498B-4D6C-8073-F738C9D1EEE3Q35172234-399DE55C-E2DB-4A19-A624-AC3AFB7C9DC9Q35557414-109AC8EE-580D-4D9D-8A94-ECCEE37812DCQ36329391-B4D1A796-E5E0-4377-BD49-485870A01CD7Q36652560-6ADBE16B-3F77-48F0-8606-FE1D5191683EQ36944147-023ECD51-2BF7-450A-8296-E6DEB90D4A51Q38617535-050E22C3-9B8A-4C5C-B7BC-0EF66BDC76E2Q38824780-6F4F9C9F-3EF4-4EAF-B1C7-B0E5462069A6Q39179437-F86D3442-3ABC-45F1-AE89-22B9A6FB95FDQ41458940-D0E43C85-5701-4435-9BB9-2AD810F082A6Q41811038-D23A564A-9FA7-459B-9658-FBF327D1AEFAQ41905591-88216EEF-C85D-4CB7-9293-2D4DF6EDD4D9Q42972489-241A6593-3DEA-483A-AA92-7D8A5F62D66BQ44635627-23B39153-47B4-4DA8-BFC7-E2814D8A8D47Q45038784-B71F1204-31B9-4AE6-82C0-6BF0D2A1A1A9Q46308426-8419657C-CEB4-4540-A7A6-942B8E316DB4Q50085980-C7E32532-0E99-417F-BA6A-1FA3985C95D3Q51292343-E9C52CBF-1EA2-4CED-94D3-3DBA872BA000Q51430102-C696B3E3-AE37-43E4-905A-5D2EC1D79045
P2860
Cholecystokinin antagonists: pharmacological and therapeutic potential.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@ast
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@en
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@nl
type
label
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@ast
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@en
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@nl
prefLabel
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@ast
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@en
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@nl
P2860
P356
P1476
Cholecystokinin antagonists: pharmacological and therapeutic potential.
@en
P2093
Rosario Herranz
P2860
P304
P356
10.1002/MED.10042
P577
2003-09-01T00:00:00Z